APA (7th ed.) Citation

M, R., TE, C., JS, L., M, S., B, Z., SW, K., . . . JR, B. (2023). Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 18(8), 1055. https://doi.org/10.1016/j.jtho.2023.04.021

Chicago Style (17th ed.) Citation

M, Reck, et al. "Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 18, no. 8 (2023): 1055. https://doi.org/10.1016/j.jtho.2023.04.021.

MLA (9th ed.) Citation

M, Reck, et al. "Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 18, no. 8, 2023, p. 1055, https://doi.org/10.1016/j.jtho.2023.04.021.